A Phase 3 interventional study of Hydroxychloroquine Sulfate Tablets and Lopinavir/ Ritonavir Oral Tablet in COVID-19, Coronavirus Infection and Virus Disease, sponsored by Cardresearch. Status unknown at 4 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.
Sponsored by Cardresearch · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing hydroxychloroquine in COVID-19 — 3 open to participants now, 3 under way, 2 of them phase 3. Hydroxychloroquine · COVID-19.
Among the 125 studies testing hydroxychloroquine in COVID-19, this one is the 6th largest by planned enrollment, is one of 118 that started in 2020, is one of 49 in phase 3, and was the 95th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →3 of the 125 studies testing hydroxychloroquine in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
Hydroxychloroquine: first FDA approval 1955 (PLAQUENIL). What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 49 · Phase 3 67 · Phase 4 11
First in 2016; this study’s year is marked. 118 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,968 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 105 across the 125 interventional studies. Of the 70 that completed or were terminated, 26 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 125 have an industry lead sponsor. The 10 most frequent:
Cardresearch is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Cardresearch has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies testing hydroxychloroquine in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 125 studies testing hydroxychloroquine in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.
In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China. A new subtype of coronavirus has been identified as the causative agent of this condition. On February 11, 43,103 cases had already been described and on this day the World Health Organization (WHO) named this disease as COVID-19. With. The disease had spread out to several countries on different continents and on March 11, WHO declared a state of worldwide pandemic. Today (April 25, 2020) there are 2,719,897 cases and 187,705 deaths documented, with a global case-fatality ratio of 6.9%.
To date, no treatment has been identified as effective in combating this disease which has been identified as with high mortality, therefore there are no specific therapeutic options. So far, efforts have been focused on the treatment of patients hospitalized with dyspnea and, although several promising drugs are being evaluated, none has demonstrated effectiveness in reducing morbidity and mortality at this stage of the disease, suggesting that perhaps the best time to use medications either before the onset of severe symptoms of respiratory distress.
Thus, we propose the use of two drugs which experimentally have shown activity against SARS-CoV2 and being used in severely ill patients with COVID-19. Our hypothesis is that perhaps using such drugs before onset of complications will allow better outcomes on this patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with RT-PCR diagnosis of COVID-19 or a clinical condition compatible with COVID-19 and respiratory symptoms, presenting:
A. Persistent dry cough associated with axillary temperature > 37.7 Celsius;
OR
B. Recent onset of Flu-like Respiratory Symptoms associated with dry cough
OR
C. Tomographic image compatible with COVID 19 infection;
Willingness to comply with study related procedures
Exclusion Criteria:
Severe respiratory clinical condition, presenting at least ONE of the criteria below:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
Drug: Hydroxychloroquine Sulfate Tablets
Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
Drug: Lopinavir/ Ritonavir Oral Tablet
Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days Plus Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
Placebo Twice a day from day 1 through day 10.
Drug: Placebo
Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
Drug pages: HydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ·
Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days plus Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
Placebo tablets - 01 tablet twice daily from day 01 through day 10.
Proportion of participants who were hospitalized for progression of COVID-19 disease
Hospitalization is defined as at least 24 hours of acute care in a hospital or similar acute care facility (emergency settings, temporary emergency facilities created for acute care of COVID-19 pandemic)
Time frame: Measuring during 28-day period since randomization (Intention to treat analysis)
Proportion of participants who died due to COVID-19 progression and/ or complications
Time frame: Measuring during 28-day period since randomization (Intention to treat analysis)
Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization
Viral load change on 03, 07, 10 and 14 after randomization (200 patients per arm)
Time frame: Measuring during 14-day period since randomization
Time to clinical improvement
Proportion of participants with clinical improvement, defined as normalization of temperature, Respiratory rate, SaO2, and cough relief (\> 50% compared to baseline measured on a visual analog scale) in the last 72 hours.
Time frame: Measuring during 28-day period since randomization
Time to clinical failure
Proportion of participants with clinical improvement, defined as as time to need for hospitalization due to dyspnea, death, need for mechanical ventilation, shock and need for vasoactive amines;
Time frame: Measuring during 28-day period since randomization
Hospitalization for any cause
Proportion of participants with hospitalization for any cause
Time frame: Measuring during 28-day period since randomization
Proportion of participants who died due to pulmonary complications
Time frame: Measuring during 28-day period since randomization
Proportion of participants who died due to cardiovascular complications
Time frame: Measuring during 28-day period since randomization
Proportion of participants who presented with adverse events
Evaluation of adverse events evaluated as associated to any of study arms
Time frame: Measuring during 28-day period since randomization
Time to improvement on respiratory scale symptoms
Proportion of participants who presented sustained improvement on respiratory scale defined as at least 48 hours of improvement.
Time frame: Measuring during 28-day period since randomization
proportion of non-adherent participants to any of study drugs
Time frame: Measuring during 10-day period since randomization
Plan to share: No
Started Jun 2020 (actual). Primary completion is estimated for Feb 2021, 7 months after the start.
Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 7 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hydroxychloroquine · Lopinavir · Ritonavir
Cardresearch